Pipeline

MMB pipeline addresses significant medically unmet needs in immuno-oncology by directly targeting T cells, immune checkpoints and tumor micro-environment.

MediMabBio’s pipelines include first-in-class antibody immunotherapies, which target an immune checkpoint inhibitor (ICI) and antagonistic or agonistic activity on the signaling receptor in different sets of immune cells. This is expected to induce anti-tumor immunity by stimulating effector T cells and inhibiting regulatory T cell activity. In order to modulate tumor microenvironment with optimized specificity and functionality, the company focuses on generating Neokine-tethered immunotherapeutic antibody, which has been developed through computational modelling and well-established MMB screening system.

Product Indication Therapeutic Modality Discovery Lead Optimization Preclinical Efficacy CMC development IND-enabling Phase I
Oncology
MMB101 Immuno- Oncology Monoclonal Antibody
MMB102 Immuno- Oncology Monoclonal Antibody
MFA011 Immuno- Oncology Fusion Antibody
MFA021 Immuno- Oncology Fusion Antibody
Inflammatory Disease
MMB301 Autoimmune Disease Neutralizing Antibody
Product Indication Therapeutic
Modality
Discovery Lead Optimization Preclinical Efficacy CMC Development IND-enabling Phase I
Oncology
MMB101 Immuno Oncology Monoclonal Antibody
MMB102 Immuno Oncology Monoclonal
Antibody
MFA011 Immuno Oncology Fusion Antibody
MFA021 Immuno Oncology Fusion Antibody
Inflammatory Disease
MMB301 Autoimmune Disease Neutralizing Antibody
Product Indication Discovery Therapeutic
Modality
Lead
Optimization
Preclinical
Efficacy
CMC
Development
IND-enabling Phase I
Oncology
MMB101 Immuno
Oncology
Monoclonal
Antibody
MMB102 Immuno
Oncology
Monoclonal
Antibody
MFA011 Immuno
Oncology
Fusion
Antibody
MFA021 Immuno
Oncology
Fusion
Antibody
Inflanmmatory Disease
MMB301 Autoimmune
Disease
Neutralizing
Antibody